CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 1/2 Study of Navitoclax Plus Vistusertib in Patients With Relapsed Small Cell Lung Cancer (SCLC) and Other Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03366103
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:31.438101+00:00
Published At: 2023-05-03T00:00:00+00:00
Record Updated At: 2023-10-17
Results Posted At: 2023-05-03
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Metastatic Malignant Solid Neoplasm", "Recurrent Lung Small Cell Carcinoma", "Recurrent Malignant Solid Neoplasm", "Refractory Malignant Solid Neoplasm", "Stage III Lung Small Cell Carcinoma, by American Joint Committee on Cancer (AJCC) v7", "Stage IIIA Lung Small Cell Carcinoma AJCC v7", "Stage IIIB Lung Small Cell Carcinoma AJCC v7", "Stage IV Lung Small Cell Carcinoma AJCC v7", "Unresectable Solid Neoplasm"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-10-17"
protocolSection.identificationModule.nctId: "NCT03366103"
protocolSection.identificationModule.officialTitle: "Phase 1/2 Study of Navitoclax Plus Vistusertib in Patients With Relapsed Small Cell Lung Cancer (SCLC) and Other Solid Tumors"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2023-05-03"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.